University of Arizona College of Medicine-Phoenix Hematology and Medical Oncology

Topics

• CAR-T cell therapy research 24
• Hemoglobinopathies and Related Disorders 18
• Acute Myeloid Leukemia Research 17
• Immunotherapy and Immune Responses 17
• Hematopoietic Stem Cell Transplantation 14
• Cancer Immunotherapy and Biomarkers 11
• Lymphoma Diagnosis and Treatment 11
• Cutaneous lymphoproliferative disorders research 8
• Platelet Disorders and Treatments 8
• Blood groups and transfusion 7
• Hemophilia Treatment and Research 7
• Chronic Lymphocytic Leukemia Research 6

Most cited

1. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022 · 629 citations · Hung Khong

2. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

   The New England journal of medicine · 2023 · 409 citations · Matthew Ulrickson

3. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).

   Blood · 2024 · 139 citations · Matthew Ulrickson

4. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.

   Nature medicine · 2022 · 261 citations · Matthew Ulrickson

5. Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 43 citations · Matthew Ulrickson

6. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 76 citations ·